Projects per year
Personal profile
Education
- 1988-1993 Ph.D., Department of Pathology and Graduate Institute of Pathology, College of Medicine, National Taiwan University
- 1982-1985 M.S., Department of Pathology and Graduate Institute of Pathology, College of Medicine, National Taiwan University
- 1975-1982 M.D., School of Medicine, China Medical College
Experience
- 2019.08- Professor, Professional Master Program in Artificial Intelligence in Medicine, College of Medicine, Taipei Medical University
- 2017.08- Professor, International Master/Ph.D. Program in Medicine, College of Medicine, Taipei Medical University
- 2016.08-2016.10 Acting Director, Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University
- 2014.02-2018.07 Director, Department of Pathology, Taipei Medical University
- 2014.02- Ph.D. Program for Cancer Molecular Biology and Drug Discovery, Taipei Medical university
- 2013.09- Deputy Director, College of Medicine, Taipei Medical university
- 2010.11- Deputy Director, Center for Teaching and Learning Development, Office of Academic Affairs, Taipei Medical University
- 2007.08- Professor, Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University
- 2006.07-2010.07 Director, Center for Faculty Development, Taipei Municipal WanFang Hospital, Taipei Medical University
- 2007.04-2009.12 Committee member, OSCE committee, Taiwan Society of Medical Education
- 2007.03-2010.07 Director, Medical Education and Research, Taipei Municipal WanFang Hospital, Taipei Medical University
- 2005.04-2010.07 Director, Clinical Skill Center and OSCE Center, Taipei Municipal WanFang Hospital, Taipei Medical University
- 2003.09-2014.10 Director, Department of Pathology, Taipei Municipal WanFang Hospital, Taipei Medical University
- 2003.08- Professor, Department of Pathology, School of Medicine, Taipei Medical University
- 2002.08-2003.07 Director, Adjunct Professor, Department of Pathology, China Medical University Hospital
- 1999.10-2003.08 Director, Department of Pathology, China Medical University Hospital
- 1999-2001 Chief and Associate Professor, Department of Pathology, China Medical College Hospital
- 1996-1997 Research Fellow of Cardiovascular Pathology and Transplantation Immunology, Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland, U.S.A.
- 1994.02-1999.09 Associate Professor, Department of Pathology, National Taiwan University College of Medicine
- 1990-1992 Research Fellow, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A.
- 1986.08-1994.01 Instructor, Department of Pathology and Graduate Institute of Pathology, National Taiwan University College of Medicine
Awards
- 2013 The Best Teaching Attending Physician Award, Taipei Medical University-Shuang Ho Hospital
- 2010.08 The Faculty Award, Taipei Medical University
- 2009 The Faulty Teaching Award, Taipei Municipal WanFang Hospital
- 2009 The Faulty Teaching Award, Taipei Medical University
- 2006.02 The Faulty Teaching Award, Taipei Municipal WanFang Hospital
- 2005 The Faulty Teaching Award, Taipei Municipal WanFang Hospital
- 2005 Outstanding Award of Contest of Published Paper and Posters, Taipei WanFang Hospital
- 1994 Professor Shu Yeh’s Award in Pathology (Ph.D. Section)
- 1987 Professor Shu Yeh’s Award in Pathology for Outstanding Pathology Research
- 1986 Qualified Pathologist in Taiwan (No. 063)
- 1986 Professor Shu Yeh’s Award in Pathology (Graduate Student Section)
Research Interests
- Pathology
- Oncologic Pathology
- Novel biomarkers in cancers
Fingerprint
Dive into the research topics where Chi-Long Chen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
The Effects of Rab3c in Chemoresistance and Tumor Immune Response in Colorectal Carcinoma( III )
8/1/22 → 7/31/23
Project: A - Government Institution › b - Ministry of Science and Technology
-
The Effects of Rab3c in Chemoresistance and Tumor Immune Response in Colorectal Carcinoma( II )
8/1/21 → 7/31/22
Project: A - Government Institution › b - Ministry of Science and Technology
-
探討代謝抑制劑和化療藥物對肝癌幹細胞的治療協同作用
7/1/21 → 2/28/22
Project: A - Government Institution › b - Ministry of Science and Technology
-
RAB3C對大腸直腸癌之抗藥性與腫瘤免疫反應影響之探討(1/3)
8/1/20 → 7/1/21
Project: A - Government Institution › b - Ministry of Science and Technology
-
Molecular Mechanisms of Secretory Rab Gtpase 3c in Promoting Colon Cancer Metastasis(3/3)
8/1/19 → 7/31/20
Project: A - Government Institution › b - Ministry of Science and Technology
-
Overexpression of synaptic vesicle protein Rab GTPase 3C promotes vesicular exocytosis and drug resistance in colorectal cancer cells
Chang, Y-C., Li, C-H., Chan, M-H., Fang, C-Y., Zhang, Z-X., Chen, C-L. & Hsiao, M., 2023, In: Molecular Oncology. n/a, n/a, 1 p.Research output: Contribution to journal › Article › peer-review
-
The activation of EP300 by F11R leads to EMT and acts as a prognostic factor in triple-negative breast cancers
Li, C-H., Fang, C-Y., Chan, M-H., Lu, P-J., Ger, L-P., Chu, J-S., Chang, Y-C., Chen, C-L. & Hsiao, M., 2023, In: The Journal of Pathology: Clinical Research. n/a, n/a, 1 p.Research output: Contribution to journal › Article › peer-review
-
Clinical assessment for non-reversal stoma and stoma re-creation after reversal surgery for rectal cancer patients after sphincter-saving operation
Kuo, C. Y., Lin, Y. K., Wei, P. L., Chi-Yong Ngu, J., Lee, K. D., Chen, C. L., Huang, Y., Chen, C. C. & Kuo, L. J., 2022, (Accepted/In press) In: Asian Journal of Surgery.Research output: Contribution to journal › Article › peer-review
Open Access -
FAS receptor regulates NOTCH activity through ERK-JAG1 axis activation and controls oral cancer stemness ability and pulmonary metastasis
Li, L. J., Chang, P. M. H., Li, C. H., Chang, Y. C., Lai, T. C., Su, C. Y., Chen, C. L., Chang, W. M., Hsiao, M. & Feng, S. W., Dec 2022, In: Cell Death Discovery. 8, 1, 101.Research output: Contribution to journal › Article › peer-review
Open Access4 Citations (Scopus) -
miR-21 upregulation exacerbates pressure overload-induced cardiac hypertrophy in aged hearts
Chang, W. T., Shih, J. Y., Lin, Y. W., Huang, T. L., Chen, Z. C., Chen, C. L., Chu, J. S. & Liu, P. Y., 2022, In: Aging. 14, 14, p. 5925-5945 21 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus)
Datasets
-
The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer
Huang, S. (Contributor), Liu, P. (Contributor), Kuo, C. (Contributor), Chen, C. (Contributor), Lee, W. (Contributor), Tsai, Y. (Creator) & Lin, Y. (Creator), Figshare, 2017
DOI: 10.6084/m9.figshare.c.3794620.v1, https://figshare.com/collections/The_G_h-PLC_1_signaling_axis_drives_metastatic_progression_in_triple-negative_breast_cancer/3794620/1
Dataset
-
Additional file 1: Table S1. of The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer
Huang, S. (Contributor), Liu, P. (Contributor), Kuo, C. (Contributor), Chen, C. (Contributor), Lee, W. (Contributor), Tsai, Y. (Contributor) & Lin, Y. (Contributor), Unknown Publisher, Jun 2 2017
DOI: 10.6084/m9.figshare.c.3794620_d1.v1, https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_Table_S1_of_The_G_h-PLC_1_signaling_axis_drives_metastatic_progression_in_triple-negative_breast_cancer/5072119/1
Dataset
-
Glucose transporter 4 promotes head and neck squamous cell carcinoma metastasis through the TRIM24-DDX58 axis
Chang, Y. (Creator), Chi, L. (Contributor), Chang, W. (Creator), Su, C. (Contributor), Lin, Y. (Contributor), Chen, C. (Creator), Chen, M. (Creator), Chang, P. M. (Creator), Wu, A. T. (Creator) & Hsiao, M. (Creator), Figshare, 2017
DOI: 10.6084/m9.figshare.c.3660368.v1, https://figshare.com/collections/Glucose_transporter_4_promotes_head_and_neck_squamous_cell_carcinoma_metastasis_through_the_TRIM24-DDX58_axis/3660368/1
Dataset
-
Supplementary Material for: The Aurora Kinases Inhibitor VE-465 is a Novel Treatment for Glioblastoma Multiforme
Lee, P. (Creator), Chen, C. (Creator), Lin, Z. (Creator), Cheng, A. (Creator), Chen, E. I. (Creator), Whang-Peng, J. (Creator) & Huang, C. F. (Contributor), Karger Publishers, 2013
DOI: 10.6084/m9.figshare.5124601.v1, https://karger.figshare.com/articles/dataset/Supplementary_Material_for_The_Aurora_Kinases_Inhibitor_VE-465_is_a_Novel_Treatment_for_Glioblastoma_Multiforme/5124601/1
Dataset
-
Additional file 3: Figure S2. of Secretory RAB GTPase 3C modulates IL6-STAT3 pathway to promote colon cancer metastasis and is associated with poor prognosis
Chang, Y. (Creator), Su, C. (Contributor), Chen, M. (Creator), Chen, W. (Creator), Chen, C. (Creator) & Hsiao, M. (Creator), Figshare, 2017
DOI: 10.6084/m9.figshare.c.3845803_d3.v1, https://springernature.figshare.com/articles/figure/Additional_file_3_Figure_S2_of_Secretory_RAB_GTPase_3C_modulates_IL6-STAT3_pathway_to_promote_colon_cancer_metastasis_and_is_associated_with_poor_prognosis/5284780/1
Dataset